Tolerability of Neoadjuvant Chemotherapy and Concurrent Chemoradiation Therapy With Gemcitabine in Muscle Invasive Bladder Cancer: Physician and Patient-Reported Outcomes

specific survival (CSS) was 83%, and two year overall survival (OS) was 69%. In the palliative group, the two year CSS and OS were 28.2%, with a median survival of 15 months. Conclusions: IMRT using daily image guidance is a feasible approach in the treatment of advanced bladder cancer, with promising loco-regional control and toxicity. Technical difficulties in the placement of fiducial markers need to be addressed. Author Disclosure: D.M. Whalley: None. H. Caine: None. L. Guo: None. A. Kneebone: None. T. Eade: None.